Sanofi (NYSE:SNY) announced its earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.74, Morningstar.com reports. The company had revenue of $8.66 billion during the quarter, compared to the consensus estimate of $8.71 billion. Sanofi had a net margin of 25.89% and a return on equity of 25.34%. The company’s quarterly revenue was down 2.3% on a year-over-year basis.
Sanofi (NYSE SNY) traded up 0.23% during trading on Friday, reaching $48.19. 573,279 shares of the company traded hands. The company’s 50-day moving average price is $47.84 and its 200 day moving average price is $46.41. Sanofi has a 52 week low of $36.81 and a 52 week high of $50.24. The firm has a market capitalization of $121.03 billion, a price-to-earnings ratio of 11.43 and a beta of 0.88.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Harbour Capital Advisors LLC bought a new position in shares of Sanofi during the first quarter worth about $113,000. Parallel Advisors LLC increased its position in shares of Sanofi by 42.5% in the second quarter. Parallel Advisors LLC now owns 2,934 shares of the company’s stock worth $139,000 after buying an additional 875 shares during the period. YorkBridge Wealth Partners LLC increased its position in shares of Sanofi by 33.7% in the second quarter. YorkBridge Wealth Partners LLC now owns 3,076 shares of the company’s stock worth $147,000 after buying an additional 776 shares during the period. Eagle Ridge Investment Management bought a new position in shares of Sanofi during the second quarter worth about $160,000. Finally, Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Sanofi by 6,188.3% in the first quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 3,773 shares of the company’s stock worth $171,000 after buying an additional 3,713 shares during the period. Institutional investors own 9.90% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Sanofi (SNY) Issues Quarterly Earnings Results” was first published by Community Financial News and is the sole property of of Community Financial News. If you are reading this piece of content on another website, it was stolen and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece of content can be read at https://www.com-unik.info/2017/08/19/sanofi-sny-issues-earnings-results-meets-expectations-updated-updated.html.
Several analysts have recently commented on the stock. Cowen and Company reiterated a “market perform” rating and issued a $52.00 target price (up previously from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. BidaskClub upgraded shares of Sanofi from a “sell” rating to a “hold” rating in a report on Saturday, August 5th. Berenberg Bank downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. Argus increased their target price on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Finally, TheStreet upgraded shares of Sanofi from a “c+” rating to a “b-” rating in a report on Monday, April 24th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $54.00.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
What are top analysts saying about Sanofi? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Sanofi and related companies.